Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
In patients starting treatment with oral anticoagulants belonging to the class of vitamin K antagonists
(e.g. warfarin), a transient hypercoagulable state may arise before the desired anticoagulant effect
becomes apparent. This transient effect may be explained by the fact that protein C, itself a vitamin K
dependent plasma protein, has a shorter half-life than most of the vitamin K dependent proteins
(i.e. II, IX and X). Subsequently, in the initial phase of treatment, the activity of protein C is more
rapidly suppressed than that of the procoagulant factors. For this reason, if the patient is switched to
oral anticoagulants, protein C replacement must be continued until stable anticoagulation is obtained.
Although Warfarin-induced skin necrosis can occur in any patient during the initiation of oral
anticoagulant therapy, individuals with congenital protein C deficiency are particularly at risk.
(See section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
In patients starting treatment with oral anticoagulants belonging to the class of vitamin K antagonists
(e.g. warfarin), a transient hypercoagulable state may arise before the desired anticoagulant effect
becomes apparent. This transient effect may be explained by the fact that protein C, itself a vitamin
K dependent plasma protein, has a shorter half-life than most of the vitamin K dependent proteins
(i.e. II, IX and X). Subsequently, in the initial phase of treatment, the activity of protein C is more
rapidly suppressed than that of the procoagulant factors. For this reason, if the patient is switched to
oral anticoagulants, protein C replacement must be continued until stable anticoagulation is obtained.
Although Warfarin-induced skin necrosis can occur in any patient during the initiation of oral
anticoagulant therapy, individuals with congenital protein C deficiency are particularly at risk.
(See section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2023-02-02T11:03:00Z · SHA-256 0185892452ffa6635104e46bba70ecf185fd6943b4e4c738d1e66a6dd19ed835 · Passage 7298f1e3d8ee23306a49661d8634fa0571f5632d57a880a812537d83fb5fb3d8 · Zeichen 108–1036 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.